TIRSKIA Trademark

Trademark Overview


On Monday, July 15, 2024, a trademark application was filed for TIRSKIA with the United States Patent and Trademark Office. The USPTO has given the TIRSKIA trademark a serial number of 98648551. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, August 14, 2024. This trademark is owned by Genentech, Inc.. The TIRSKIA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use in oncology and hematology
tirskia

General Information


Serial Number98648551
Word MarkTIRSKIA
Filing DateMonday, July 15, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateWednesday, August 14, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for use in oncology and hematology

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, July 15, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGenentech, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events


Event DateEvent Description
Monday, July 15, 2024NEW APPLICATION ENTERED
Monday, July 15, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 13, 2024ASSIGNED TO EXAMINER
Wednesday, August 14, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 14, 2024NON-FINAL ACTION WRITTEN
Wednesday, August 14, 2024NON-FINAL ACTION E-MAILED